JP2012531402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531402A5 JP2012531402A5 JP2012516975A JP2012516975A JP2012531402A5 JP 2012531402 A5 JP2012531402 A5 JP 2012531402A5 JP 2012516975 A JP2012516975 A JP 2012516975A JP 2012516975 A JP2012516975 A JP 2012516975A JP 2012531402 A5 JP2012531402 A5 JP 2012531402A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- composition
- transient
- cognitive
- term
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 208000010877 cognitive disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 230000001052 transient effect Effects 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 230000007774 longterm Effects 0.000 claims 8
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 6
- 208000026139 Memory disease Diseases 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000003951 lactams Chemical group 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 208000019914 Mental Fatigue Diseases 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 230000037007 arousal Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 230000003188 neurobehavioral effect Effects 0.000 claims 2
- 235000008160 pyridoxine Nutrition 0.000 claims 2
- 239000011677 pyridoxine Substances 0.000 claims 2
- 125000002181 pyridoxine group Chemical group 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 150000003573 thiols Chemical group 0.000 claims 2
- 229940011671 vitamin b6 Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000007787 long-term memory Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22037609P | 2009-06-25 | 2009-06-25 | |
| US61/220,376 | 2009-06-25 | ||
| US30564110P | 2010-02-18 | 2010-02-18 | |
| US61/305,641 | 2010-02-18 | ||
| PCT/IL2010/000506 WO2010150261A1 (en) | 2009-06-25 | 2010-06-24 | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531402A JP2012531402A (ja) | 2012-12-10 |
| JP2012531402A5 true JP2012531402A5 (enExample) | 2013-08-08 |
| JP5770173B2 JP5770173B2 (ja) | 2015-08-26 |
Family
ID=43386090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516975A Expired - Fee Related JP5770173B2 (ja) | 2009-06-25 | 2010-06-24 | 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120264781A1 (enExample) |
| EP (1) | EP2445498A1 (enExample) |
| JP (1) | JP5770173B2 (enExample) |
| CN (1) | CN102481291B (enExample) |
| AU (1) | AU2010264074B2 (enExample) |
| BR (1) | BRPI1015231A2 (enExample) |
| CA (1) | CA2766107A1 (enExample) |
| EA (1) | EA023758B1 (enExample) |
| MX (1) | MX2011013775A (enExample) |
| NZ (1) | NZ597319A (enExample) |
| WO (1) | WO2010150261A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| US20110294859A1 (en) | 2008-07-29 | 2011-12-01 | Alcobra Ltd. | Substituted pyridoxine-lactam carboxylate salts |
| WO2011061743A1 (en) * | 2009-11-18 | 2011-05-26 | Alcobra Ltd. | Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders |
| EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| KR20150063040A (ko) * | 2012-09-26 | 2015-06-08 | 유로드러그 레버러토리즈 비. 브이. | 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제 |
| TW201605443A (zh) * | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 治療ｘ染色體脆折症及相關病症的方法 |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| CN103989625B (zh) * | 2014-05-15 | 2016-03-02 | 金伟华 | 一种由美他多辛作为药用成分制备的栓剂及其制备方法 |
| CN103976970A (zh) * | 2014-06-06 | 2014-08-13 | 程奉平 | 美他多辛缓释片的制备方法 |
| CN108122610A (zh) * | 2016-11-29 | 2018-06-05 | 复旦大学附属儿科医院 | 基于儿童孤独症谱系评定评分参数的分析系统 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1286161A (en) * | 1970-01-21 | 1972-08-23 | Soc D Etudes Prod Chimique | Pyridoxine mono-esters |
| FR2172906A1 (en) * | 1972-02-25 | 1973-10-05 | Fabre Sa Pierre | Salts of 3-pyridyl methanol derivs - vasodilators |
| IT1131856B (it) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
| IT1244507B (it) | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| IT1263957B (it) | 1993-02-23 | 1996-09-05 | Impiego terapeutico del pirrolidon carbossilato di piridossina | |
| US5942530A (en) * | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
| GB0007419D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
| US20020192303A1 (en) | 2001-06-01 | 2002-12-19 | Stefan Arver | Treatment of side effects associated with alcohol consumption |
| WO2003003981A2 (en) | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
| IL159813A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
| ES2323451T7 (es) * | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| US6541043B2 (en) | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6913769B2 (en) | 2003-02-18 | 2005-07-05 | Brian Douglas Oslick | Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption |
| ES2235626B1 (es) | 2003-11-10 | 2006-11-01 | Almirall Prodesfarma, S.A. | Formas de administracion masticables, no comprimidas dosificadas individualmente. |
| US20050271739A1 (en) | 2004-06-08 | 2005-12-08 | Wang Xiang H | Methods and compositions for accelerating alcohol metabolism |
| US8124653B2 (en) * | 2004-06-25 | 2012-02-28 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
| CN1301108C (zh) | 2004-10-15 | 2007-02-21 | 山东齐都药业有限公司 | 美他多辛分散片及其制备方法 |
| TW200803896A (en) * | 2005-09-22 | 2008-01-16 | Sb Pharmco Inc | Method of improvement of cognitive function |
| US20070248696A1 (en) | 2006-04-25 | 2007-10-25 | Mind Sports Nutrition Inc. | Composition and method for enhancing neuromuscular facilitation and cognitive functions |
| KR100877600B1 (ko) | 2006-11-30 | 2009-01-08 | 재단법인서울대학교산학협력재단 | 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물 |
| IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| US20110294859A1 (en) * | 2008-07-29 | 2011-12-01 | Alcobra Ltd. | Substituted pyridoxine-lactam carboxylate salts |
-
2010
- 2010-06-24 WO PCT/IL2010/000506 patent/WO2010150261A1/en not_active Ceased
- 2010-06-24 NZ NZ597319A patent/NZ597319A/en not_active IP Right Cessation
- 2010-06-24 MX MX2011013775A patent/MX2011013775A/es active IP Right Grant
- 2010-06-24 CN CN201080033413.XA patent/CN102481291B/zh not_active Expired - Fee Related
- 2010-06-24 EP EP10737637A patent/EP2445498A1/en not_active Withdrawn
- 2010-06-24 BR BRPI1015231A patent/BRPI1015231A2/pt not_active IP Right Cessation
- 2010-06-24 AU AU2010264074A patent/AU2010264074B2/en not_active Ceased
- 2010-06-24 JP JP2012516975A patent/JP5770173B2/ja not_active Expired - Fee Related
- 2010-06-24 CA CA2766107A patent/CA2766107A1/en not_active Abandoned
- 2010-06-24 EA EA201270068A patent/EA023758B1/ru not_active IP Right Cessation
- 2010-06-25 US US13/380,215 patent/US20120264781A1/en not_active Abandoned
-
2012
- 2012-07-03 US US13/541,568 patent/US8710067B2/en not_active Expired - Fee Related
-
2016
- 2016-03-18 US US15/074,580 patent/US20160199362A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531402A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| WO2010129864A3 (en) | Methods and compositions for studying, imaging, and treating pain | |
| JP2013516442A5 (enExample) | ||
| JP2010535252A5 (enExample) | ||
| HRP20161121T1 (hr) | Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2013528600A5 (enExample) | ||
| JP2010512413A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2016505512A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| JP2008539268A5 (enExample) | ||
| ES2968840T3 (es) | Compuestos de aminocarbonilcarbamato y su uso en el tratamiento de trastornos hipercinéticos tales como el TDAH | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2021505575A5 (enExample) | ||
| JP2015531764A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| MX2014013452A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
| JP2017526695A5 (enExample) | ||
| JP2016537338A5 (enExample) |